Kangfeng Biotechnology (Shanghai) Co., Ltd. (formerly Kangfeng Biotechnology (Shanghai) Co., Ltd.) was founded in 2013 and is a leading cryomedical technology platform company with a unique advantage in the field of minimally invasive interventional cryotherapy. With unique liquid nitrogen cryoablation technology, the company is committed to building a comprehensive product portfolio, focusing mainly on two major treatment areas: (i) vascular intervention to treat major cardiovascular diseases, such as atrial fibrillation and high blood pressure, etc., and (ii) through natural channels to treat respiratory, urinary, and digestive diseases such as chronic obstructive pulmonary disease, asthma, airway stenosis, bladder cancer, stomach cancer, and esophageal cancer.
The company's core team members have more than ten years of R&D experience and practical engineering application experience for medical device-related products. They specialize in cryo-ablation technology, and have successfully developed more than 10 pioneering international/domestic cryo-ablation products. They have obtained 105 patents, and 43 patents are being applied for.
At present, the company has successfully developed a number of leading domestic or international cryoablation products, and is committed to making advanced cryoablation technology benefit a wide range of patients.
CEO： Kejian Li
Market： Hong Kong motherboard
Listing Date： 12/30/2022